FDA reviewing Anacor's dermatitis candidate

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) said FDA accepted for filing an NDA for crisaborole ( AN2728) to treat mild to moderate atopic dermatitis in children and adults. Its PDUFA date is Jan. 7, 2017.

Crisaborole is a topical borinic acid ester that inhibits phosphodiesterase-4 ( PDE-4) and the production of tumor necrosis factor (TNF) alpha, IL-12 and IL-23. In July 2015, Anacor Chief Commercial Officer Vince Ippolito said the treatment has the potential to exceed $1 billion in annual net revenues (see BioCentury Extra, July 13, 2015). ...